Market Closed - Nasdaq 01:30:00 18/05/2024 am IST 5-day change 1st Jan Change
90.61 USD -2.55% Intraday chart for BioNTech SE -1.16% -14.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care Stocks Softer Friday Afternoon MT
Sector Update: Health Care MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program MT
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports RE
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program MT
Autolus Therapeutics' Q1 Loss Widens, Licensing Revenue Rises MT
Evercore ISI Starts BioNTech With In Line Rating, $100 Price Target MT
BIONTECH : UBS remains Neutral ZD
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
HC Wainwright Raises BioNTech SE Price Target to $113 From $107, Maintains Buy Rating MT
BIONTECH : Deutsche Bank reaffirms its Neutral rating ZD
TD Cowen Adjusts BioNTech Price Target to $98 From $95, Maintains Hold Rating MT
BMO Capital Adjusts BioNTech Price Target to $122 From $123, Maintains Outperform Rating MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday MT
BIONTECH : Goldman Sachs reiterates its Neutral rating ZD
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Sector Update: Health Care Stocks Advance in Monday Afternoon Trading MT
Sector Update: Health Care MT
BIONTECH : Jefferies gives a Neutral rating ZD
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco MT
BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline MT
Dpa-AFX Overview: COMPANIES from 06.05.2024 - 15:15 DP
Chart BioNTech SE
More charts
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
83.34 EUR
Average target price
105.4 EUR
Spread / Average Target
+26.45%
Consensus
  1. Stock Market
  2. Equities
  3. BNTX Stock
  4. News BioNTech SE
  5. SVB Securities Adjusts BioNTech's Price Target to $224 from $223, Keeps Outperform Rating
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW